Annual Report 2022

NOTESTOTHE CONSOLIDATED FINANCIAL STATEMENTS For the year ended 31 December 2022 92 The United Laboratories International Holdings Limited Annual Report 2022 5. REVENUE AND SEGMENT INFORMATION (Continued) Segment information (Continued) (b) Other segment information (Continued) For the year ended 31 December 2021 Intermediate Bulk Finished products medicine products Unallocated Consolidated RMB’000 RMB’000 RMB’000 RMB’000 RMB’000 Amortisation of intangible assets 1,840 – 14,775 3 16,618 Depreciation of right-of-use assets 4,815 3,551 2,082 641 11,089 Depreciation of property, plant and equipment 451,505 88,348 47,152 6,145 593,150 Net loss on disposal of property, plant and equipment 1,489 1,726 86 – 3,301 Written off of property, plant and equipment 7,255 8,408 417 – 16,080 Impairment losses recognised (reversed) 947 2,027 (362) 293,947 296,559 (c) Geographical information The revenue by geographical market (irrespective of the origin of the goods) based on the location of the customers are presented below: Revenue from external customers 2022 2021 RMB’000 RMB’000 PRC, including Hong Kong (country of domicile) 8,962,740 7,607,485 Europe 631,282 530,715 India 556,336 688,842 Middle East 48,294 27,844 South America 297,594 234,769 Other Asian regions 587,835 480,380 Other regions 250,181 133,403 11,334,262 9,703,438